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Most cellular processes are driven by simple biochemical mechanisms such as protein and lipid phospho-
rylation, but the sum of all these conversions is exceedingly complex. Hence, intuition alone is not
enough to discern the underlying mechanisms in the light of experimental data. Toward this end, math-
ematical models provide a conceptual and numerical framework to formally evaluate the plausibility of
biochemical processes. To illustrate the use of these models, here we built a mechanistic computational
model of PI3K (phosphatidylinositol 3-kinase) activity, to determine the kinetics of lipid metabolizing
enzymes in single cells. The model is trained to data generated upon perturbation with a reversible
small-molecule based chemical dimerization system that allows for the very rapid manipulation of the
PIP3 (phosphatidylinositol 3,4,5-trisphosphate) signaling pathway, and monitored with live-cell micro-
scopy. We ﬁnd that the rapid relaxation system used in this work decreased the uncertainty of estimating
kinetic parameters compared to methods based on in vitro assays. We also examined the use of Bayesian
parameter inference and how the use of such a probabilistic method gives information on the kinetics of
PI3K and PTEN activity.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
In order to understand signaling networks and their role in the
regulation of the cell as well as their deregulation in disease, it is
necessary to be able to measure their constituents, such as proteins
and their PTMs (Post Translational Modiﬁcations) and small
molecules involved in signaling, at the single cell level and at
multiple time points. There are now many experimental methods
that are capable of such measurements. These include on the one
hand ﬂuorescent microscopy techniques such as FRET (Förster
Resonance Energy Transfer) and FRAP (Fluorescence Recovery after
Photobleaching) for live cells27 and, on the other hand, more high-
throughput techniques such as mass cytometry8 that however
destroy the cells during measurement.
Such single cell measurements are important to understanding
how signaling pathway dynamics can inﬂuence pathway output
and ultimately the phenotype of the cell. Population-scale mea-
surement techniques such as mass spectrometry or Western Blot
can only attain average measurements over many cells. However,
measuring single cell dynamics can uncover novel mechanisms
that are not apparent from measuring at the population scale.
For example, the occurrence of NFjB oscillations across cellpopulations23 and the dynamic properties of certain signaling pro-
teins (e.g., ERK;3 and calcium7 have only become apparent through
single-cell measurement techniques.
Another powerful approach to explore signaling is to monitor
cells not just in their natural resting state, but upon perturbation
of the activity of some of their components. Perturbation methods
that artiﬁcially control intracellular enzymes have been developed
using a variety of approaches. These include small molecule inhibi-
tors, RNAi and multiple genomic methods, such as CRISPR genome-
editing. One particularly powerful tool is chemical dimerization,
where one is able to rapidly switch on and off enzyme activity
non-invasively through rapid cell entry of small molecules. The
resulting changes in signaling dynamics can then be tracked in live
cells.24
Hypothesis prediction and validation using single cell measure-
ments usually need to be aided by mathematical modeling. In
many cases, where the biochemistry of the system is known, sets
of ordinary differential equations are constructed from the under-
lying chemical reactions in the system. What is deﬁned as the sys-
tem can range from a full signaling pathway9 to a particular set of
reactions.18 Such models have been used for a range of purposes,
such as quantifying and understanding the source of heterogeneity
in apoptosis,2 and deﬁning feedback in signaling pathways.14 More
generally, such models may serve to formalize hypotheses and
assumptions about the data and can also be used to predict novel
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drug on a signaling pathway.25
Despite the advantages of constructing such physicochemical
models to provide mechanistic insight, there are many difﬁculties
to overcome in their formulation and validation before they can be
considered useful tools. The interactions that make up the model
(the model structure) are often unknown and, for physicochemical
models, it is a non-trivial task to search systematically over all pos-
sible models that explain the data, although recently methods have
begun to address this.4 Once a model structure has been chosen,
the parameters, such as initial conditions and rate constants, may
be unknown and need to be estimated from the data. In the cases
where this is necessary, such unknown parameters may not be
identiﬁable given the data and model structure.16 There are many
methods of parameter optimization (e.g., simulating annealing,
particle swarm, multiple shooting, etc.), with associated advan-
tages and disadvantages.30 Bayesian inference is one such method
that is suited to smaller models and provides a framework to quan-
tify parameter uncertainty and formally compare alternative
models.12
Here we illustrate the application of these modeling methods to
phosphoinositide signaling. We show, using the perturbation data
obtained via chemical dimerization in Ref. 13, how Bayesian infer-
ence methods can help with model choice and with quantifying the
uncertainty of parameter estimates based on such data. A model
describing PIP3 homeostasis is introduced and we show that the
in vivo kinetics of some of the enzymes controlling PIP3 metabo-
lism (PI3K and PTEN) are much faster than previous estimates from
in vitro experiments suggested.
2. Results
2.1. Experimental data
The experimental data is described in detail in Feng et al.13
Brieﬂy, the chemical dimerization system consists of a reversible
chemical dimerizer rCD1 that binds to two proteins simultane-
ously, SNAP-tag and FKBP. The covalently binding SNAP-tag pro-
tein is fused to a protein localized in the plasma membrane (Lck)
and to a ﬂuorescent tag to form the construct Lck-ECFP-SNAPf.
The induction of phosphatidylinositol 3-kinase (PI3K) can be inves-
tigated by fusing the mRFP-FKBP construct (FKBP bound to a ﬂuo-
rescent tag) with the inter-Src homology 2 (iSH2) domain from
p85. p85 is the regulatory subunit of PI3K. Hence, when rCD1 is
transfected into the cell, it causes p85 translocation to the plasma
membrane, as rCD1 binds to both Lck-ECFP-SNAPf and mRFP-
FKBP-iSH2. Henceforth, we will refer to this complex as iSH2.Figure 1. The quantiﬁcation of iSH2 and PHAkt in experiment 1 (left) and experimen
ﬂuorescence was calculated. The error bars represent the standard error of the mean us
added to the cells. Reproduced with permission from Ref. 13.p85 then binds with the endogenous catalytic subunit p110a, thus
activating PI3K.28
In addition to triggering PI3K activity in HeLa cells, the produc-
tion of its product PI(3,4,5)P3 (PIP3), which PI3K converts from PIP2,
is also measured over time. This is done by quantifying transloca-
tion of the pleckstrin homology (PH) domain of Akt fused to a ﬂu-
orescent protein (EGFP-PHAkt, henceforth referred to as PHAkt) to
the plasma membrane.13
We used two experiments based on the method above to esti-
mate the parameters of a model of PIP3 metabolism, presented in
Ref. 13. In the ﬁrst one (Fig. 1 (left)), the ratio of plasma membrane
to cytoplasmic ﬂuorescence of PHAkt and iSH2 is followed over
time. There are two perturbations in this experiment. The ﬁrst is
the addition of rCD1, the small molecule dimerizer that brings
iSH2 to the plasma membrane thus activating PI3K. The second
is the addition of FK506 40 min after stimulation, a competitive
dimerizer with rCD1 that causes iSH2 to be removed from the
PM, thus deactivating PI3K rapidly. As PIP3 levels are high at this
stage of the experiments, rapidly stopping the PIP3 supply allows
one to follow PIP3 metabolism in a relaxation type of experiment
in intact single cells. Hence, this experimental setup is useful to
monitor the dynamics of activation and deactivation of PI3K, as
well as PIP3 levels and its downstream effectors.
The second experiment (Fig. 1 (right)), is similar to the ﬁrst in
that the chemical dimerizer and FK506 are used to activate and
deactivate PI3K and, again, the ratio of plasma membrane to cyto-
plasmic ﬂuorescence of PHAkt and iSH2 is followed over time. The
difference in this experiment is that the measurements only
started 27.5 min after rCD1 addition when it is assumed the sys-
tem has reached a steady state. Also, the PTEN inhibitor H2O2
was an added perturbation at 30 min post-rCD1 addition, that is,
after 2.5 min of the recorded traces. Hence, this experiment aimed
to study the effect of PTEN inhibition on an already steadily acti-
vated PI3K.
For each experiment, a number of technical replicates were per-
formed (see Supplementary part 1 for the breakdown of the exper-
iments), resulting in traces from 22 cells for experiment 1 and 17
cells from experiment 2. Some of the traces were of poor quality
for the ﬁrst experiment. Therefore 14/22 single-cell traces were
used in further analysis (see Supplementary part 1).
2.2. Data normalization
A prerequisite for modeling is to have all data normalized in a
way so that it can be jointly used. After the data was scaled across
both experiments (see Supplementary part 1), the distribution of
steady state values of PHAkt from experiment 1 was compared tot 2 (right). For both experiments, the ratio of plasma membrane to cytoplasmic
ing 3 independent replicates. The arrows show when and what perturbations were
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Figure 2. The distribution of the steady state (before FK506 addition) of experiment
1 for the PHAkt trace compared to the initial condition distribution of experiment 2
before (green) and after (orange) correction.
2870 A. MacNamara et al. / Bioorg. Med. Chem. 23 (2015) 2868–2876the distribution of initial values from experiment 2. The steady
state from experiment 1 was taken as the mean value of the 10
measurements before addition of the FKBP binder FK506. This data
across all single cells should have the same distribution as the ini-
tial values from experiment 2, as in experiment 2 measurements
commenced at a steady state post-rCD1 activation. As can be seen
from Figure 2, the distributions are not the same (t = 15.6,
p <0.001; Fig. 2) but their range is similar. Subtracting the differ-
ence in mean values from the 2 distributions from the experiment
2 distribution matches the steady state distributions across the 2
experiments (t = 0.29, p = 0.77). Hence, this correction was used
on the presumption that it corrected for a shift in overall ﬂuores-
cence, that is, technical variation between the 2 experiments.
2.3. Parameter optimization
As mentioned in the introduction, there are a number of differ-
ent approaches to identifying the parameters of physicochemical
models and they can be divided into a number of categories.
Often, concentrations of the constituent species can be measured
using quantitative methods such as Western blot or mass spec-
trometry. It is more difﬁcult to ﬁnd accurate prior knowledge of
reaction parameters (such as binding constants), as these are
poorly represented in the literature and in vitro methods of esti-
mating such values are limited models of what actually occurs in
the cell. This is because the in vitro environment is relatively
homogenous compared to the complexity (space, constituents,
etc.), of the cell. This seems to be especially true for reactions hap-
pening on membranes as these are difﬁcult to mimic in the test
tube. Because of this, reaction parameters tend to be estimated
indirectly (i.e., inferred) using available data, in particular the con-
centration changes of their substrates and products.
There are a set of methods that attempt to ﬁnd a single (or mul-
tiple) set of parameter values that minimize the distance between
the data and the model. These methods use advanced algorithms to
efﬁciently and quickly identify these solutions. Even though they
cannot guarantee to ﬁnd the very best set of parameter values, in
practice they have been shown to work well in ﬁnding the best
or close to the best solutions.6 Reporting not just one but multiple
sets of parameters is essential as there is pervasive uncertainty on
the estimates. This is due to various factors ranging from the
unavoidable experimental noise, the technical limitations when
measuring certain components, the need to measure proteins
under different conditions, and fundamental constraints due to
the nature of the models.30 Hence, one can rarely rely on a single
value.A more exhaustive approach, but in turn more computationally
expensive, is to estimate the probability distribution of the param-
eters. The probability distribution of a parameter assigns a proba-
bility to all possible values for that parameter in the model. Such
distributions take into account experimental variation, that is, the
uncertainty of the experiment measurements used for model vali-
dation, and model non-identiﬁability. Bayesian statistics provides
an appropriate framework to perform these analyses.21,32,12,17
In this paper, we use Bayesian inference to estimate these
parameter probability distributions. Such distributions are termed
the posterior distributions in Bayesian terminology and are a pro-
duct of the prior distribution (i.e., one’s prior knowledge or belief of
the parameter) and the likelihood of the parameters given the data.
These distributions are impossible to ﬁnd analytically for non-triv-
ial biological models so they must be estimated through sampling.
One such method for sampling is the Markov Chain Monte Carlo
(MCMC) walk. MCMC is based on the premise that the number of
visits during the walk to a particular point in the parameter space
is proportional to the posterior probability. Hence, if the walk con-
tains enough steps, it should build an estimate of the distribution
that is close to the true posterior.
Parameter estimation for all models was performed using
Bayesian inference. The Python package BayesSB was used, which
samples the posterior distribution using a Markov Chain Monte
Carlo (MCMC) walk and imposing a Metropolis-Hastings (MH) cri-
terion, a condition that helps the exploration of the parameter
space, at each step.12 The methodology used is detailed in Box 1
of Ref. 12. The models were also built using the Python package
PySB.22 All scripts are available as Supplementary materials.
3. Modeling the data
3.1. Model detail
When building a model, the key biological processes that the
measurements represent need to be taken into account. In this sys-
tem, it was clear that the enzymes PI3K and PTEN needed to be
included in a model of PIP3 dynamics. However, we also wanted
to test if there were additional biological mechanisms that needed
to be included to fully explain the data. At the same time, we did not
want to over-ﬁt the data by attempting to model non-biological
(technical) variation: a measurement is in general a function of
the underlying biology and biological/technical noise. In most
cases, one is trying to understand the underlyingmechanism and/or
quantify the biological noise, and therefore an estimate of the tech-
nical noise needs to be made. For the data in this study, it is clear
that iSH2 is activating PI3K and hence is causative of the increase
in PHAkt as a result of PI3K increasing PIP3 at the PM. From the
PHAkt single cell traces (Fig. 3A), in addition to a general monotonic
increase in the PM/cytoplasmic ratio, there is considerable variation
or ﬂuctuation at shorter time scales. While this is probably mostly
noise, it is interesting to test whether any of this variation is biolog-
ical in nature. This can be inspected by looking at the correlation in
the iSH2 and PHAkt traces for each single cell and speciﬁcally asking
the question: can the previous nmeasurements (at t  1. . . t  n) of
iSH2 and PHAkt explain PHAkt at time t better than PHAkt alone (at
t  1. . . t  n). One such formal test of this relationship is the
Granger causality test.15
For the 14 single-cell traces, we tested Granger causality up to
the addition of FK506. The traces after this time point were not
included as FK506 addition causes a strong causal link between
iSH2 and PHAkt and would hence confound results; iSH2 is ‘pulled’
from the plasma membrane, which in turn affects PHAkt, that is,
here the direction of causality is obvious at this time point. The
value of n in the Granger causality test was deﬁned by testing over
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Figure 3. (A) The mechanism of the short-term ﬂuctuations in the single-cell traces for iSH2 and PHAkt was examined using Granger causality. For each time point t for PHAkt,
the previous n points were taken for iSH2 and tested if they had any explanatory power for PHAkt. This was performed for all times t up to the addition of FK506. The iSH2
trace was then randomized in short sections, which conserved the overall dynamics of the trace but randomized the short-term variation (red trace). The Granger causality
was then compared between the randomized and real iSH2 traces across all single-cells. The example shown here is replicate 1, cell 1 from experiment 1. (B) A comparison of
the Granger causality between true and randomized iSH2 traces in explaining PHAkt. There was no signiﬁcant difference between true and random (t = 0.61, p = 0.55, n = 14).
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Granger causality as averaged over all traces (see Supplementary
part 3). The result was n = 1, meaning that taking any previous
time-points beyond the immediately previous one from
iSH2/PHAkt did not improve the prediction of PHAkt at time t.
Then, by randomizing each single-cell iSH2 trace (see
Supplementary part 3), we tested whether the true iSH2 traces
were any better at predicting PHAkt compared to randomized
iSH2 traces across each single cell (n = 14). Figure 3B shows that
this was not the case (t = 0.61, p = 0.55), which suggests that
the variation among them is not mechanistically connected and
training a model to ﬁt this variation (which can be viewed as noise)
would likely result in over-ﬁtting.3.2. Testing model structures
Two mechanistic models of PIP3 metabolism were developed to
investigate the rates of catalysis of the enzymes that control PIP3
dynamics. Both were based on the general scheme where the con-
version of PIP2 to PIP3, and vice versa, is controlled by 2 enzymes,
PI3K and PTEN, respectively. Following mass-action kinetics, where
one describes the system in terms of its elementary reactions, the
system can be represented as follows:
PIP2 þ PI3K$ PI3K : PIP2 ! PIP3 þ PI3KPIP3 þ PTEN$ PTEN : PIP3 ! PIP2 þ PTEN
where the enzyme binds (reversibly) to the substrate, producing an
enzyme–substrate complex, and then the product and enzyme are
released from this complex. Converting such a representation to a
set of ordinary differential equations leads to a relatively complex
model with six reaction rate parameters to measure or infer, as well
as the added enzyme–substrate species. Given that we only had
data for a limited number of components and conditions, we would
not be able to determine any of these parameters in any meaningful
way. One way to simplify these reactions is to use Michaelis–
Menten kinetics, which makes the assumption that the enzyme–
substrate complex and its reactants are in a steady state; such an
assumption reduces the number of parameters that need to bemeasured or inferred, and simpliﬁes the model as there is no vari-
able needed to describe the enzyme–substrate complex:
PIP2!
rf
PIP3
PIP3!
rr
PIP2
where the reaction rates are:
rf ¼ kcat fPI3K:PIP2=ðKm f þ PIP2Þ
rr ¼ kcat rPTEN:PIP3=ðKm r þ PIP3Þ
It should be pointed out that, although Michaelis–Menten
kinetics describe in vitro assays that measure enzyme kinetics
accurately, the assumptions do not necessarily apply to in vivo
conditions.10 Using Michaelis–Menten kinetics requires 2 parame-
ters for each enzymatic reaction (kcat and Km), which, given that the
parameter estimates were largely unconstrained (i.e., they were
not restricted to a narrow range of values), would likely make such
parameters unidentiﬁable given our data. For this reason, the reac-
tions were reduced so that the conversion from substrate to pro-
duct depended linearly on the substrate and was controlled by a
single rate parameter, that is, assuming that the amount of the sub-
strate is much smaller than the corresponding Km (PIP2 << Km_f and
PIP3 << Km_r). Then, deﬁning kf = kcat_f/Km_f and kr = kcat_r/Km_r, the
reaction rates become:
rf ¼ kfPI3K:PIP2
rr ¼ krPTEN:PIP3
Using one of the principles of mass-action kinetics, where the
rate of change in the concentration of the products of these reac-
tions is proportional to the reactants’ concentrations, the represen-
tations above can be converted to a system of ordinary differential
equations:
d½PIP3
dt
¼ kfPIP2:PI3K krPIP3:PTEN
d½PIP2
dt
¼ krPIP3:PTEN kfPIP2:PI3K
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above equations are based on a number of assumptions besides the
aforementioned simpliﬁcation of the kinetics:
1. We assumed that the PHAkt traces were representative of PIP3
at the plasma membrane. Endogenous PIP3 also binds to PHAkt.
However, endogenous levels are notoriously low in resting cells,
signiﬁcantly below the kd of the PH domain to PIP3. Hence, the
assumption was that (i) the PIP3 molecules binding to PHAkt were
those newly anabolised by the introduced iSH2, and that (ii)
PIP3  PHAkt binding occurs on a much faster time scale compared
to the change in dynamics of PIP3 caused by the presence of iSH2 at
the plasma membrane (so the rate parameter for PIP3  PHAkt
could be ignored).
2. We assumed that, on addition of the competitive ligand
FK506, the release of PHAkt from the plasma membrane was caused
by PTEN activity converting PIP3 to PIP2. This assumption was sup-
ported by showing that PIP3 degradation was not affected by
changes in FK506 concentration above 0.1 lM (Fig. 2D from Ref.
13).
3. We assumed that the principles of mass-action kinetics (a 3D,
well-mixed environment) apply at the plasma membrane, where
these reactions take place (see Section 4).
4. We assumed that, over the time-frame of the experiment, the
individual reactions are irreversible.
5. The PTEN concentration (see below for how PI3K is treated in
the model) is constant and the total phosphoinositide concentra-
tion (PIP2 + PIP3) is conserved.
Both of the initial models were based on the above assumptions
but differed in how active PI3K was included in the model. The
activation of PI3K during chemical dimerization involves a number
of steps, that is, the binding of rCD1 to iSH2, its translocation to the
plasma membrane and also the activation of the catalytic subunit
p110a by this complex. In modeling, there is always a trade-off
between the scope of the model and the quantity of data available
to validate the model. In this case, the experimental design is most
suited to understanding the mechanism of PTEN activity (in terms
of deﬁning its catalytic parameters) and less well designed to
deﬁning PI3K activity, due to the number of reactions whose
parameters can only be estimated by a single (iSH2) trace. There
is more information available about PTEN kinetics in this experi-
mental design as FK506 addition deactivates PI3K, leaving PHAkt
dynamics to be mainly inﬂuenced by PTEN. H2O2 is a PTEN inhibi-
tor. The change in PHAkt dynamics after H2O2 addition demon-
strates that a phosphatase (and not, i.e., a kinase) is responsible
for PIP3 metabolism. Hence, we decided to test 2 approaches that
combined the steps that lead to PI3K activation and hence make
the models more tractable:
(i) Model A (see Fig. 4) tested the hypothesis that iSH2 becomes
saturated at the plasma membrane as iSH2 is in excess of p110aPIP2 PIP3
A
PTEN
PIP2 PIP3
B
PTEN
mRFP-FKBP-iSH2
p110
Figure 4. The 2 models compared in Section 3.2. Model A assumes that iSH2 is
saturated at the plasma membrane. Model B assumes that active PI3K is directly
proportional to the quantity of iSH2 at the plasma membrane.(see Fig. 4). Unfortunately, such a model precludes using the
iSH2 experimental traces for validation as the quantity of iSH2 is
equal to two terms in the model—free iSH2 and iSH2 bound to
p110a (or active PI3K). In this model active PI3K is not constant
and the following equation is added to the system:
iSH2þ p110a!
ks
PI3K
d½PI3K
dt
¼ ksiSH2:p110a
(ii) Model B in Figure 4 represents the scaled trace of iSH2 as an
explicit term in the model such that:
PI3K ¼ iSH2data
d½PI3K
dt
¼ d½iSH2
data
dt
Hence, the iSH2 scaled trace was explicitly included in Model B
for a number of reasons: (1) the experimental design would pro-
vide the most information about the mechanism behind the
dynamics of PIP3 deactivation, and hence PTEN activity, and not a
mechanism of PI3K activation and (2) we wanted to test the
assumption that the quantity of iSH2 at the plasma membrane
was linearly proportional to the quantity of catalytically active
PI3K. Such a formulation presumes that p110a, the catalytic sub-
unit of PI3K that iSH2 binds to, is not limited at the plasma mem-
brane and the kinetics of iSH2/p110a binding does not introduce
non-linearity.
To compare models A and B, we tested how well both ﬁtted the
PHAkt data, which is represented by ‘PIP3’ in both models. There are
a number of ways of formally comparing models. In general, one
wants to ﬁt the data as well as possible while also producing a
model as parsimonious as possible. The Akaike information crite-
rion (AIC)1 and Bayesian information criterion (BIC)26 are 2 such
measures that provide a score that balances the ﬁt of data and
the number of free parameters in the model. Although there are
differences in their underlying assumptions, in practice, their only
difference is that the BIC penalizes model complexity more heavily.
Using both measures yielded the following results:Mean AIC Mean BICModel A 2468 2487
Model B 4916 4928For both measures, Model A gives a lower score, which suggests this
model is a better ﬁt to the data. Indeed, visualizing the ﬁt across all
single cells (Supplementary part 4), supports the choice of Model A
over B.
Another criterion that can be used in this context is the Bayes
factor, which, for 2 compared models, is the ratio of the overlap
between the likelihood and prior for each model. The Bayes factor
can be advantageous to use as it takes into account parameter
uncertainty and can aid in model selection in the case where the
2 models have similar likelihoods (i.e., they ﬁt the data equally
well12), and are similarly complex (and hence AIC/BIC cannot dis-
tinguish between them). However, it requires complex computa-
tions, and hence its calculation is computationally very expensive
and prone to errors. In this case, due to the large difference in like-
lihoods (or ﬁt) between Models A and B, it was unnecessary to cal-
culate the Bayes factor as Model A was clearly a better description
of the data, on average, across the single cells, as summarized by
the AIC and BIC criteria.
Table 1
The mean and standard deviation (SD) of the estimate of the PTEN rate parameter (kr)
for each single-cell from experiment 1
Replicate Cell SD Mean
1 1 0.0004 0.0258
1 2 0.0002 0.0264
1 3 0.0002 0.0251
1 4 0.0002 0.0182
1 5 0.0008 0.0290
2 1 0.0024 0.0381
2 3 0.0003 0.0147
2 4 0.0002 0.0122
2 5 0.0002 0.0182
2 6 0.0002 0.0109
3 1 0.0006 0.0360
3 7 0.5582 1.0290
3 9 0.0003 0.0185
3 11 0.0002 0.0154
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this point as the goal of this model comparison was to ﬁnd a model
structure (or structures) that could feasibly explain the data.
Hence, the PHAkt traces were scaled between 0 and 1 across all
experiments and the initial conditions (both quantities and kinetic
parameters) were set to arbitrary values. Such dimensionless mod-
eling comes with the assumption that (a) the model will behave
similarly despite the change in the difference of orders of magni-
tude among the variables and (b) the MCMC algorithm ﬁnds the
optimum parameters for each candidate model. We return to (a)
in the discussion below and (b) was veriﬁed by testing for conver-
gence of the posterior probabilities of the model parameters
(Supplementary part 5).
Prior to considering parameter identiﬁability, comparing the
likelihoods of each model explaining the single cell traces of
PHAkt favors the saturation model over that of iSH2 having a linear
relationship with active PI3K.
3.3. Testing for covariance and parameter identiﬁability
As well as providing an estimate of the parameters that best ﬁt
the data, Bayesian inference also gives information about parame-
ter identiﬁability and uncertainty through the probability distribu-
tions of the parameters. Figure 5 shows the probability
distributions across the 14 single cell measurements for the PTEN
rate parameter (kr), when trained against experiment 1 alone. It is
clear that the experimental design is well suited to obtaining accu-
rate measurements of this parameter. The mean standard devia-
tion across all cells is 0.0004 A1 s1 (excluding the outlier
replicate 3, cell 7) with a mean of 0.022 A1 s1 (where A repre-
sents the arbitrary unit of concentration in the model). In ModelReplicate 1, Cell 1 Replicate 1, Cell 2
Replicate 1, Cell 5 Replicate 2, Cell 1
Replicate 2, Cell 5 Replicate 2, Cell 6
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Figure 5. The probability distributions for the PTEN rate parameter (kr) across the 14 singA, after the addition of the competitive dimerizer FK506, it is
assumed that PI3K is deactivated immediately. Hence, the rate of
PIP3 loss from the plasma membrane, represented by the PHAkt
trace, is controlled solely by the rate of PTEN catalysis and this
parameter can be estimated with high conﬁdence. As well as the
probability distributions of kr, Figure 5 also shows the kr value
(red line) that produced the best ﬁt to the data for each single cell.
This is not necessarily the same as the mean of the distribution, as
one would expect. The reason for this is that the red line is the peak
of the joint probability distribution across all estimated parame-
ters, which is not necessarily the same as the single (or marginal)
distribution for a single parameter (see Table 1).Replicate 1, Cell 3 Replicate 1, Cell 4
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Figure 7. The difference in the mean estimates of the PI3K parameter (kf) when
ﬁtting to experiment 1 or experiment 1/2 in combination (t = 2.1, p = 0.04).
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Figure 8. A summary of the ﬁt of Model A to the data from experiment 2 (the
addition of H2O2 to inhibit PTEN). The black line with the grey border represents
the mean ± the standard deviation of the simulation of PIP3 using Model A ﬁtted to
the data from experiments 1 and 2 combined (n = 14, the ﬁt to experiment 1 is show
in Supplementary Fig. S8). The red line with error bars represents the mean ± the
standard deviation of experiment 2 for all single-cell traces (n = 17). As noted, the
measurements from experiment 2 commenced 27.5 min after rCD1 additions,
whereas the model is simulated from t = 0. The downwards spike in the experi-
mental traces is an experimental artifact.
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estimating the PTEN rate parameter, the PI3K (kf) and PTEN (kr)
parameters show strong linear covariation (Fig. 6, mean Pearson’s
correlation = 0.84, n = 14), albeit over a narrow range for both kf
and kr. This is a consequence of the linked nature between the for-
ward and reverse reactions in Model A; even though kr is strongly
constrained by the removal of active PI3K by FK506, within this
range it is only possible to infer the ratio of kf and kr, that is, of
the forward and reverse reactions.
3.4. The added information from the H2O2 experiment
(experiment 2)
For the next step, we tested what information could be gained
from experiment 2: the addition of H2O2 to inhibit PTEN. For each
PHAkt trace in experiment 1 (n = 14), we trained the reaction rate
parameters in Model A to both the data from experiment 1 and
experiment 2 combined. In order to do this, the PHAkt traces from
experiments 1 and 2 needed to be paired. This was done by taking
the closest steady state values from the distributions (as shown in
Fig. 2, see also Supplementary part 1) between the 2 experiments.
Figure 7 shows that the added experiment further constrained the
PI3K rate parameter kf (experiment 1 mean standard deviation(SD) 3.6 e5; experiment 1 and 2 mean SD 9.1 e6; n = 14) and also
changed the mean estimate across all single cells of kf (t = 2.1,
p = 0.04, n = 14). Figure 8 shows the ﬁt of Model A trained to exper-
iment 1/2 combined against the data from experiment 2. Hence,
from Figure 7, one can quantify, in terms of the change in the kf
probability distributions from ‘experiment 1’ to ‘experiment 1/2’,
the added information that is gained from experiment 2.
4. Discussion
In this paper, we have illustrated the value of mathematical
models to study biochemical processes in general, and PIP3 regula-
tion in particular. We have discussed key aspects to keep in mind
when building models, such as the level of granularity and scope
of the model and the need for appropriate normalization. We have
A. MacNamara et al. / Bioorg. Med. Chem. 23 (2015) 2868–2876 2875listed all assumptions that went into building our model; these
assumptions have to always be kept in mind as they may be vio-
lated in the experiments the model is based on, hence affecting
potentially the conclusions made. The insight that a model can pro-
vide is largely determined by the experimental data used to build
it. As illustrated here, the ability of chemical dimerizers and their
competing ligands to rapidly activate and deactivate enzymes
makes the technology an important tool in modeling signaling
pathways. By simulating PIP3 dynamics using a simple model
incorporating PI3K and PTEN, we have shown that such an exper-
iment can help identify the kinetics of enzymes and decrease
uncertainty in their estimation. However, it is also clear that iden-
tiﬁability of parameter values is also highly dependent on the
model structure and the assumptions underlying the model.
For the model comparison and exploration above, arbitrary
units were used for the concentrations of the model species.
Despite the limitations in terms of quantitative insight, such
dimensionless models are useful tools. Importantly, dimensionless
models require much less information and can be built without
quantitative data. Some biological information could be included
with this approach; in the model the quantity of PIP2 was an order
of magnitude greater than the maximum amount of PIP3 across all
cells and hence the quantity PIP2 + PIP3 was kept constant.
In order to provide the parameters dimension, thereby making
them biologically interpretable, two problems must be solved:
1. The model must be adapted to take account of the two-di-
mensional environment at the plasma membrane where these
reactions take place: As explained above, mass-action and
Michaelis–Menten kinetics assume the reactions take place in a
homogenous well-mixed environment. However, phospholipids
(PIP2 and PIP3) and their regulating enzymes (PI3K and PTEN,
among others) interact at the plasma membrane, which greatly
increases the rate of interaction between the molecules. One way
to reﬂect this in a model is to introduce a scaling factor that is
the plasma membrane area to cell volume ratio.31 More compli-
cated biophysical models can also be used that explicitly include
factors such as diffusion and electrostatic forces.20 One of the chal-
lenges of modeling signaling pathways is judging the importance
of including such additional parameters and whether models such
as these can be connected to mass-action models of signaling (i.e.,
multi-scale modeling 11).
2. Secondly, the initial concentrations/amounts of the model
species must be found. For plasma membrane-bound models such
as phosphoinositides (PIP2 and PIP3), it is most accurate to use
units such as ‘number of molecules’/lm2. Although such estimates
can be found from literature, it is more difﬁcult deﬁning the
amount of PI3K at the plasma membrane. Total cell concentrations
of PI3K have been estimated13 but this total includes cytoplasmic
and plasma membrane-bound populations.
Regarding the model itself, it has been shown that the mecha-
nisms controlling PI3K activity are much more complex than rep-
resented here.29 However, the simple model was able to ﬁt the
data well. This suggests that the more complex feedback mecha-
nisms that regulate PI3K were either not active during the time-
frame of the experiments in this study, or perhaps any additional
mechanisms were masked by the stronger kinetics of the for-
ward/reverse reactions controlled by PI3K/PTEN. In either case, fur-
ther experiments would be needed to build a more complex model
that would allow for understanding additional PI3K regulation.
A similar approach to the one taken in this study was performed
by Bandara et al.5 They also used a chemical dimerization system
to infer the parameters of PIP3 metabolism. The main difference
is that, instead of the competitive dimerizer FK506 to deactivate
PI3K, they used a small molecule inhibitor. The consequence of this
is that active PI3K could not be inhibited as quickly as when using
FK506. This necessitated the use of extra parameters in their modelto explain active PI3K inhibition although, in comparison, they
explored additional experiments to constrain these parameters.
The goal of their study was to optimally design an experiment
based on the timing and concentration of inhibition that would
reduce uncertainty in the parameter estimations. To quantify the
uncertainty of their parameter estimates, instead of calculating
the probability distributions as here, they performed sensitivity
analysis. This deﬁned the uncertainty of a parameter as inversely
proportional to the sensitivity of the model prediction to changes
in the parameter value. Hence, both their approach and that taken
here provide a practical comparison of the advantages/disadvan-
tages of probabilistic parameter inference, some of which we out-
line below.
Bayesian approaches have a much larger computational cost for
calculating probability distributions when estimating model
parameters from data, which limits the size of the models that
can be applied. In addition, Bayesian parameter inference is more
complex in nature and requires more expertise. However, such
approaches to parameter inference provide a sound framework
to deal with parameter uncertainty. Cellular signaling pathways
have been well-studied for the past 30 years and a large amount
of information has accumulated.19 Such information includes sig-
naling interactions, binding afﬁnity estimates from multiple
in vitro studies and concentration estimates of pathway con-
stituents (small molecules, proteins, lipids, etc.) This information
can be included in Bayesian parameter inference in the form of a
prior distribution, or one’s belief in the distribution of the param-
eter. As mentioned above, model comparison in the form of the
Bayes factor, is an additional advantage of Bayesian inference,
especially in the case where the competing models have similar ﬁts
and complexity.12 Additionally, Bayesian inference allows for
direct examination of covariance in the data by examining joint
distributions between pairs of parameters in a model. This can for-
mally identify regions of the model where identifying the true
parameter values is difﬁcult, or impossible given the experimental
data (e.g., the on/off rates of two molecules binding).
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